Answers are grounded in this paper and cite their sources.
The respiratory syncytial virus (RSV) burden and cost-effectiveness of infant RSV immunisation was evaluated by comparing seven strategies in terms of costs and Quality-Adjusted Life Years (QALYs) from health care payer's perspective: no universal immunisation, year-round or seasonal maternal vaccination (MV), year-round or seasonal nirsevimab (NmAb) at birth, seasonal NmAb+catch-up for infants ≤ 6-month and a combined MV+NmAb with catch-up strategy. Seasonal NmAb+catch-up averted the most disease, while seasonal MV averted the least, but had the lowest incremental cost-effectiveness ratio (€11,276/QALY gained) at current list prices (MV €186, NmAb €778). Extensive trade-offs between NmAb and MV show at which cost per dose which strategy would be deemed cost-effective. At a willingness to pay of €35,000/QALY gained, seasonal NmAb + catch-up was preferred if NmAb < €210; otherwise, seasonal or year-round MV was preferred when MV < €220 or <€75, respectively. The combined strategy became preferred at low MV and NmAb costs. Besides price level, cost-effectiveness was most sensitive to RSV hospital burden.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: